Regulus Therapeutics Inc (NASDAQ: RGLS) is 120.31% higher on its value in year-to-date trading and has touched a low of $0.77 and a high of $3.79 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RGLS stock was last observed hovering at around $2.68 in the last trading session, with the day’s gains setting it 0.14%.
Currently trading at $2.82, the stock is 48.07% and 78.75% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.07 million and changing 5.03% at the moment leaves the stock 96.51% off its SMA200. RGLS registered 171.15% gain for a year compared to 6-month gain of 120.31%. The firm has a 200-day simple moving average (SMA200) of -$5.85.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 93.15% loss in the last 1 month and extending the period to 3 months gives it a 127.42%, and is 19.49% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.06% over the week and 16.12% over the month.
Regulus Therapeutics Inc (RGLS) has around 30 employees, a market worth around $57.42M and $0.00M in sales. Distance from 52-week low is 266.23% and -25.59% from its 52-week high. The company has generated returns on investments over the last 12 months (-135.05%).
Regulus Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.21.The EPS is expected to grow by 67.88% this year.
Regulus Therapeutics Inc (RGLS) Top Institutional Holders
33 institutions hold shares in Regulus Therapeutics Inc (RGLS), with institutional investors hold 33.36% of the company’s shares. The shares outstanding are 20.22M, and float is at 12.25M with Short Float at 0.45%. Institutions hold 32.89% of the Float.
The top institutional shareholder in the company is Federated Hermes, Inc. with over 3.88 million shares valued at $10.93 million. The investor’s holdings represent 5.92% of the RGLS Shares outstanding. As of Dec 30, 2023, the second largest holder is FMR, LLC with 2.92 million shares valued at $8.24 million to account for 4.46% of the shares outstanding. The other top investors are NEA Management Company, LLC which holds 1.95 million shares representing 2.97% and valued at over $5.49 million, while DAFNA Capital Management, LLC holds 1.70% of the shares totaling 1.11 million with a market value of $3.13 million.
Regulus Therapeutics Inc (RGLS) Insider Activity
The most recent transaction is an insider sale by Hagan Joseph P,the company’sChief Executive Officer. SEC filings show that Hagan Joseph P sold 14,580 shares of the company’s common stock on Jan 18 ’24 at a price of $1.19 per share for a total of $17359.0. Following the sale, the insider now owns 57112.0 shares.
Regulus Therapeutics Inc disclosed in a document filed with the SEC on Jan 18 ’24 that CALSADA CRISPINA (Chief Financial Officer) sold a total of 5,468 shares of the company’s common stock. The trade occurred on Jan 18 ’24 and was made at $1.19 per share for $6510.0. Following the transaction, the insider now directly holds 5782.0 shares of the RGLS stock.
Still, SEC filings show that on Jan 18 ’24, Aker Christopher Ray (Sr. VP & General Counsel) disposed off 5,468 shares at an average price of $1.19 for $6510.0. The insider now directly holds 10,056 shares of Regulus Therapeutics Inc (RGLS).
